Merck Sees 2022 Sales Up Nearly 20%, Mostly on Molnupiravir
The drugmaker said sales of the COVID-19 drug were $952 million in the fourth quarter, and it expects another $5 to $6 billion of sales for the drug in 2022.
Merck